or Try an Advanced Search...

    ETF Components for CANC - Tema Oncology ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    REGN C 1.28 5.38
    MRK B 0.52 5.27
    ILMN F 0.66 3.66
    NVS B 0.61 3.40
    EXAS F -8.96 3.14
    ARGX C -0.91 2.87
    GILD F -0.52 2.82

    Represented by ETF Holdings

    Keywords: Medicine S&P 500 Antibiotics Biopharmaceutical Biotechnology Infectious Diseases Inflammation Nasdaq 100 Ophthalmology Animal Health Cancer Cardiovascular Disease Clinical Research Colorectal Cancer Lab Testing Life Sciences Macular Degeneration Medication Molecular Diagnostics Respiratory Diseases
    Industries: Drug Manufacturers - Major Biotechnology Diagnostics & Research

    Recent News for Tema Oncology ETF & its Holdings

    Date Stock Title
    May 9 GILD Gilead's Kite, Arcellx share phase 3 trial design for CAR-T multiple myeloma asset
    May 9 ARGX argenx SE (ARGX) Q1 2024 Earnings Call Transcript
    May 9 GILD Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
    May 9 EXAS Exact Sciences Corporation (NASDAQ:EXAS) Q1 2024 Earnings Call Transcript
    May 9 EXAS Exact Sciences (EXAS) Q1 Revenues Rise Y/Y, Gross Margin Down
    May 9 EXAS Q1 2024 Exact Sciences Corp Earnings Call
    May 9 GILD Gilead's FOCUS Program Helps Zero In on Early HIV Detection
    May 9 MRK Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
    May 9 MRK Merck says Keytruda failed as first-line therapy for uterine cancer
    May 9 MRK Health Canada Approves KEYTRUDA® for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapy
    May 9 REGN Regeneron’s gene therapy triumphs twice, restoring hearing in children
    May 9 MRK Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
    May 9 EXAS Exact Sciences Corp (EXAS) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth ...
    May 9 ARGX argenx misses top-line and bottom-line estimates; updates FY24 outlook
    May 9 GILD Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight
    May 9 ARGX argenx Reports First Quarter 2024 Financial Results and Provides Business Update
    May 9 EXAS Exact Sciences (EXAS) Q1 2024 Earnings Call Transcript
    May 9 EXAS Exact Sciences Corporation (EXAS) Q1 2024 Earnings Call Transcript
    May 8 EXAS Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates
    May 8 EXAS Exact Sciences down 17% on quarterly bottom line miss, maintaining 2024 guidance
    Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.
    Index Fund Private Equity Investment Management
    Back to the Main CANC Page...